Introduction {#s1}
============

Multidrug-Resistant Tuberculosis (MDRTB) refers to *Mycobacterium tuberculosis* (TB) strains with *in vitro* resistance to the two most effective anti-tuberculosis drugs, isoniazid (INH) and rifampin (RFP). MDRTB has become a major barrier to achieving successful control of TB, as therapy is less effective, associated with more adverse events and is more costly to treat when compared with standard first line therapy. According to a recent WHO report, approximately 490,000 MDRTB cases occur globally every year, corresponding to approximately 4.8% of the world\'s TB cases [@pone.0006914-World1], [@pone.0006914-World2]. The importance of addressing drug resistant TB is further amplified by more recent reports on extensively drug resistant TB (XDRTB) [@pone.0006914-Ghandi1], which represented 7% of MDR isolates referred to supranational reference laboratories from 2000--2004 [@pone.0006914-World1].

Inadequate treatment of MDRTB can lead to worse patient outcomes, while increasing the risk of extensive drug resistance [@pone.0006914-Mukherjee1]--[@pone.0006914-Chan1]. Guidelines for the management of MDRTB have been developed over the past decade, but there is little evidence based on randomized controlled trials to support current recommendations [@pone.0006914-Mitnick1], [@pone.0006914-Caminero1]. Moreover, treatment strategies have varied significantly and are difficult to compare between populations [@pone.0006914-Caminero1], [@pone.0006914-Laserson1]. This lack of evidence reflects a lack of political and financial will, in part from the perception that MDRTB is of limited epidemiological importance [@pone.0006914-Mitnick1]. It also reflects the limited number of second line drugs that are available and the unequal distribution of access depending on local resources. The recent recognition of the increasing magnitude of MDRTB, along with the poor prognosis of XDRTB has created the impetus for a more evidence-based approach to the treatment of MDRTB.

Recently, standardized definitions were established to allow comparison between treatment groups and facilitate the development of a more evidence-based approach [@pone.0006914-Laserson1], [@pone.0006914-World3]. We therefore decided to complete a systematic review of MDRTB treatment regimens. Where appropriate, we performed a meta-analysis to explore associations between MDRTB treatment outcomes and the clinical and microbiological factors that influence outcome. We aimed to identify all the published literature and to establish the best possible evidence base of clinical and microbiological predictors of treatment response.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

Several search strategies were used to identify potentially relevant studies. Search strategy was developed by the investigators (Johnston and Shahidi) with consultation of a medical librarian.

1.  A systematic search was conducted to identify eligible studies in the following databases: EMBASE (1980 to Week 50, 2008), MEDLINE (1965 to Week 50, 2008), International Pharmaceutical Abstracts (1970 to November 2008) and BIOSIS (1969 to Week 50, 2008). Keywords included tuberculosis, TB, multi\$, drug\$, multidrug, multi-drug, MDRTB, MDR TB, MDR-TB, extensively drug resistant, extensively drug-resistant, XDRTB, XDR TB, XDR-TB, drug resistant tuberculosis.

2.  Key word search was conducted in EBM Reviews - Cochrane Database of Systematic Review, Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials (all to 4th Quarter 2008). Citations were reviewed, revealing no systematic reviews on this subject.

3.  Keyword and title search of Web of Science was performed using the terms tuberculosis, TB, tb, multiple drug resistant, multiple drug resistance, multi-drug resistance, multi-drug resistant, multi-drug-resistant, drug resistant, MDR, MDRTB, extensively drug resistant, XDRTB.

4.  Hand searching of the following journals: *International Journal* of Tuberculosis and Lung Disease, *Chest*, *American Journal of Respiratory & Critical Care Medicine*, and *Clinical Infectious Disease*.

5.  Bibliographies of full text articles were examined for eligible studies.

6.  Results were limited to English articles. Abstracts were included in search results.

Selection of Studies {#s2b}
--------------------

Studies obtained from the literature search were checked by title and citation. If an article appeared relevant, the abstract was reviewed. Relevant abstracts were examined in full text. Inclusion criteria were as follows: an original study; reported in English; reported treatment outcomes in a population of adult, culture-confirmed MDRTB patients; reported outcomes presented in a format allowing for comparison with other studies. Exclusion criteria were as follows: exclusive surgical series; exclusive use of first-line therapy in the treatment protocol.

Validity assessment {#s2c}
-------------------

Studies were assessed for quality, with only high quality studies included for analysis. High quality studies reported outcomes on at least 10 patients; were prospective cohort, retrospective consecutive cohort, consecutive case control or randomized control in design; reported an average treatment duration of ≥12 months within an average follow-up duration ≥18 months; reported basic demographic data; reported less than 1/3 default or lost to follow-up. When study populations overlapped, we included the more recent and larger study population in the analysis. If the smaller population provided data on an outcome or variable not reported in the larger study, results were included for that specific variable.

Outcome measures {#s2d}
----------------

Measured outcomes reflect the definitions proposed by *Laserson et al.*, and published in recent WHO guidelines [@pone.0006914-Laserson1], [@pone.0006914-World3]. Successful outcomes included patients meeting the definition of *Cure* or *Treatment Completed*. Unsuccessful outcomes included patients meeting the definition of *Death, Defaulted*, *Failed* or *Transferred Out*. When follow-up data was used, relapse was included as an unsuccessful outcome. To homogenize data, end-of-treatment (EOT) and follow-up (FUP) outcomes were separated for analysis. FUP outcomes refer to post-treatment follow-up, with follow-up duration measured in months. If studies were unable to meet WHO definitions, reviewers established outcomes to reflect these definitions. Certain studies reported data that precluded the use of WHO outcome definitions, and were not included for analysis. Several variables--including co-morbidities, demographic variables, microbiological profile, disease presentation and disease characteristics---were collected for outcome analysis. Analysis of these variables pooled both EOT and FUP outcomes given the paucity of homogenous data for individual variables. Where appropriate we contacted investigators for additional data as well as for clarification of their findings.

Data extraction and statistical analysis {#s2e}
----------------------------------------

Data abstraction was performed by two reviewers using a standardized abstraction form. When there was disagreement, the relevant paper was reviewed and differences were resolved by consensus. Microsoft Excel (version 12.0), STATSDirect version 2.7.6 (StatsDirect Ltd, Cheshire, UK), and STATA version 10.0 (STATA Corporation, College Station, Texas) software were used for data entry and analysis. Study characteristics and treatment outcomes were summarized in tables. Data related to treatment outcomes were pooled from published studies as described above. We pooled the proportion of successful outcome, death, default, transfer of care, and failure across studies using a random-effects meta-analysis. Heterogeneity of studies was estimated by calculating I^2^ and Cochrane p values. The heterogeneity of binary covariates was estimated through p values. The overall effect of the dichotomous data was carried out by using a random effects analysis because of study heterogeneity (I^2^ \>50%, p\<0.05) and measured by odds ratio with 95% confidence intervals \[95%CI\].

Results {#s3}
=======

We identified 9835 citations from our initial electronic database search. Of these, 116 articles were identified for full text review. A further 17 articles were identified through manual search, bibliographic search, and reviewer suggestions. Of the 133 articles reviewed in full text, 36 articles, representing 31 distinct patient populations were analyzed based on our *a priori* inclusion-exclusion criteria and quality assessment [@pone.0006914-Avendano1]--[@pone.0006914-Yew2]. Ninety-four studies were removed prior to analysis: 36 lacked adequate data on the patient population or outcomes; 17 evaluated an inappropriate population or overlapped with a larger study population; 5 reported outcomes based on first line therapy alone; 22 did not meet criteria for treatment duration or follow-up; 9 reported more than one-third default or loss to follow-up; 5 reported outcomes on \<10 patients; and 3 were excluded based on study design ([Figure 1](#pone-0006914-g001){ref-type="fig"}).

![Forest plots of covariates.](pone.0006914.g001){#pone-0006914-g001}

The 36 articles chosen for review reported treatment outcomes on 31 study populations from 21 countries on 5 continents ([Table 1](#pone-0006914-t001){ref-type="table"}). The study periods ranged from 1973 to 2006. The majority were retrospective chart reviews, with five prospective cohorts [@pone.0006914-Escudero1], [@pone.0006914-Masjedi1], [@pone.0006914-Suarez1], [@pone.0006914-Uffredi1], [@pone.0006914-VanDeun1] and one retrospective case control [@pone.0006914-ORiordan1]. The average study population (range) was 210 (24--1407). The majority of patients were male, with a mean of 68% (48--92) across all studies. In 30 studies with available data, the mean age was 40 years. All studies reported on patients with a prior history of treatment. In studies with available data, 84% (32--100) of patients had previously received anti-tuberculous therapy. The average number of drugs to which resistance was shown was 4.1 for studies reporting resistance. For those reporting first and second-line resistance, the average number of drugs to which there was resistance was 4.4.

10.1371/journal.pone.0006914.t001

###### Summary of studies.

![](pone.0006914.t001){#pone-0006914-t001-1}

  Study Period    Design   Sample Size       Region         Endpoint     Male (%)   HIV (%)   DM (%)   ETOH (%)   BMI (%)   SMR (%)   CAV (%)   SRG (%)   PRT (%)   6DR (%)   FQU (%)   XDR (%)               Covariates Analyzed
  -------------- -------- ------------- ---------------- -------------- ---------- --------- -------- ---------- --------- --------- --------- --------- --------- --------- --------- --------- ---------------------------------------------
  1986--1999        RC         40            Canada         33M FUP         53         0        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1993--2006        RC         540            USA             EOT           \-         7        \-        \-        \-        \-        \-        \-        \-        \-        \-         3                          XDR
  2001--2004        RC         45        Czech Republic       EOT           82         0        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1982--2000        RC         48             USA         EOT, 24M FUP      67        23        \-        \-        \-        \-        \-         6        \-        \-        \-        \-                       HIV, SRG
  1992--1996        RC         299           Taiwan       EOT, 39M FUP      72         0        \-        \-        \-        92        \-        \-        94        \-        42        \-                  GEN, SMR, PRT, FQU
  2003--2005        RC         87          Uzbekistan         EOT           61        \-        \-        23        \-        \-        \-        \-        \-        \-        \-        \-                         ETOH
  1998--2000        PC         25            Spain        EOT, 24M FUP      92         0        \-        \-        \-        \-        \-         8        88        32        72        \-                  SRG, PRT, 6DR, FQU
  1995--1999        RC         127           Italy            EOT           65        12        9         5         \-        87        \-        \-        \-        \-        58        \-             GEN, HIV, DM, ETOH, SMR, FQU
  1973--1983        RC         134            USA           51M FUP         69        \-        \-        \-        \-        87        \-        \-        \-        55        \-        \-                     GEN, SMR, 6DR
  1994--2005        RC         407            USA             EOT           59        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1989--1998        RC         24            Canada           EOT           75         4        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  2000              RC         167           Latvia           EOT           78        \-        \-        \-        \-        \-        \-        \-        24        \-        \-        \-                          PRT
  2000--2004        RC         608        Russian Fed         EOT           83         1        \-        43        43        \-        \-         9        \-        \-        \-         5             GEN, HIV, ETOH, BMI, SRG, XDR
  1996--2005        RC         211           Korea            EOT           61         0        14        \-        37        \-        76        30        29        \-        \-        20           GEN, DM, BMI, CAV, SRG, PRT, XDR
  2000--2002        RC        1407           Korea            EOT           74        \<1       \-        \-        13        \-        43         4        \-        \-        \-         5                GEN, BMI, CAV, SRG, XDR
  1998--2004        RC         155           Korea            EOT           53         0        15        1         28        86        71        23        10        \-        \-        17      GEN, DM, ETOH, BMI, SMR, CAV, SRG, PRT, XDR
  2000              RC         204           Latvia           EOT           77         1        6         62        19        \-        78        10        19        \-        \-        \-           GEN, DM, ETOH, BMI, CAV, SRG, PRT
  2002--2006        PC         43             Iran            EOT           63         0        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          GEN
  1996--1999        RC         75             Peru        EOT, 40M FUP      49         1        \-        \-        43        \-        \-        \-        \-        \-        \-        \-                       GEN, BMI
  1999--2002        RC         646            Peru          25M FUP         60         1        \-        \-        \-        \-        \-        15        \-        90        \-         7                     SRG, 6DR, XDR
  1994--1997        RC         81             USA             EOT           67        38        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1982--2004        CC         42        United Kingdom       EOT           50         0        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1996--2002        RC         141         Argentina          EOT           48         0        \-        \-        \-        \-        \-         6        \-        \-        \-        \-                          SRG
  1998--2000        RC         142           Korea            EOT           79         0        \-        \-        \-        \-        \-        \-        \-        33        26        \-                     GEN, 6DR, FQR
  1992--2002        RC         491        South Africa      24M FUP         59         3        \-        29        \-        \-        \-         6        91        \-        \-        \-               GEN, HIV, ETOH, SRG, PRT
  2000--2002        RC         244        Russian Fed         EOT           87         0        \-        \-        \-        \-        \-        12        \-         7        \-        \-                       SRG, 6DR
  1997--1999        PC         298            Peru            EOT           57        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1992--1999        RC         158           Turkey           EOT           87        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1991--1994        RC         25             USA             EOT           56         0        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1992--2004        RC         252           Turkey           EOT           81        \-        \-        \-        \-        \-        \-        26        \-        \-        85        \-                     GEN, SRG, FQU
  1999--2002        RC         118        Phillipines         EOT           86        \-        \-        \-        \-        \-        \-        \-        96        \-        \-        \-                          PRT
  1998--1999        PC         45            France           EOT           53        20        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1997--1999        RC         58          Bangladesh     EOT, 24M FUP      84        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1989--2000        RC         44           Vietnam       EOT, 15M FUP      59         0                  \-        \-        \-        \-        \-        \-        \-        \-        \-                          \-
  1990--1997        RC         72          Hong Kong      EOT, 25M FUP      74         0        \-        \-        \-        90        51        \-        \-        \-        85        \-                  GEN, SMR, CAV, FQR
  1990--2000        RC         72          Hong Kong          EOT           74         0        \-        \-        \-        \-        \-        \-        \-        \-        40        \-                          FQU

RC = Retrospective cohort, PC = prospective cohort, CC = case control, GEN = gender, HIV = HIV positive, DM = diabetes, ALC = alcohol abuse, BMI = low body mass index, SMR = smear positive, CAV = cavitary disease, PRT = prior therapy, 6DR = six drug resistance, FQR = fluoroquinol.

In the 26 trials with a total 4959 patients reporting EOT outcomes 62% \[95% CI 57--67\] of patients met the definition of successful treatment, while 11% [@pone.0006914-Laserson1]--[@pone.0006914-Bartu1] of patients died and 8% [@pone.0006914-Sharma1]--[@pone.0006914-Avendano1] failed therapy ([Table 2](#pone-0006914-t002){ref-type="table"}). The default rate was 13% [@pone.0006914-Laserson1]--[@pone.0006914-Escudero1], while 2% [@pone.0006914-World1]--[@pone.0006914-Mukherjee1] had their care transferred to another jurisdiction. In 9 trials with a total of 1583 patients reporting outcomes at follow-up, the mean follow-up duration was 27 [@pone.0006914-Chiang1]--[@pone.0006914-Jeon1] months ([Table 3](#pone-0006914-t003){ref-type="table"}). The percentage with successful outcomes at follow-up was 64% \[56--72\], while 14% [@pone.0006914-World3]--[@pone.0006914-Goble1] died, 13% [@pone.0006914-Mitnick1]--[@pone.0006914-Granich1] defaulted, 5% [@pone.0006914-World2]--[@pone.0006914-Laserson1] failed therapy, 1% \[0--2\] had their care transferred and 2 \[0--4\] relapsed. Based on the data provided, the percentage of patients presenting with re-infection, rather than relapse cannot be determined.

10.1371/journal.pone.0006914.t002

###### End of Treatment Outcomes.
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  Author (Reference)                       Population   Successful Outcome                         Death                                               Default                                           Transfer of Care                                         Failure
  --------------------------------------- ------------ -------------------- --------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------- ----------------------------------------------------
  Bartu [@pone.0006914-Bartu1]                 45               33                                  11                                                    1                                                     0                                                    0
  Chiang [@pone.0006914-Chiang1]              299              153                                  28                                                    87                                                    0                                                    31
  Cox [@pone.0006914-Cox1]                     87               54                                  13                                                    12                                                    0                                                    8
  Escudero [@pone.0006914-Escudero1]           25               21                                   0                                                    4                                                     0                                                    0
  Ferrara [@pone.0006914-Ferrara1]            126               49                                  11                                                    21                                                    16                                                   29
  Granich [@pone.0006914-Granich1]            338              231                                  49                                                    10                                                    48                                                   0
  Hersi [@pone.0006914-Hersi1]                 18               8                                    5                                                    1                                                     4                                                    0
  Keshavjee [@pone.0006914-Keshavjee1]        608              400                                  31                                                   119                                                    0                                                    58
  Kim HR [@pone.0006914-Kim1]                 211              132                                  19                                                    7                                                     7                                                    46
  Kim DH [@pone.0006914-Kim2]                 1407             637                                  144                                                  453                                                   108                                                   65
  Kwon [@pone.0006914-Kwon1]                  155              102                                  10                                                    15                                                    6                                                    22
  Leimane [@pone.0006914-Leimane1]            204              135                                  14                                                    26                                                    0                                                    29
  Masjedi [@pone.0006914-Masjedi1]             43               29                                   8                                                    0                                                     0                                                    6
  Mitnick 2003 [@pone.0006914-Mitnick3]        75               55                                   5                                                    14                                                    0                                                    1
  Narita [@pone.0006914-Narita1]               81               46                                  26                                                    9                                                     0                                                    0
  O\'Riordan [@pone.0006914-ORiordan1]         42               25                                   3                                                    9                                                     4                                                    1
  Palmero [@pone.0006914-Palmero1]            141               73                                  27                                                    28                                                    0                                                    13
  Park [@pone.0006914-Park1]                  142               63                                   4                                                    41                                                    15                                                   19
  Suarez [@pone.0006914-Suarez1]              298              136                                  32                                                    34                                                    0                                                    96
  Telzak [@pone.0006914-Telzak1]               25               16                                   1                                                    0                                                     0                                                    8
  Torun [@pone.0006914-Torun1]                252              193                                  18                                                    25                                                    0                                                    16
  Tupasi [@pone.0006914-Tupasi1]              118               71                                  18                                                    16                                                    1                                                    12
  Uffredi [@pone.0006914-Uffredi1]             45               26                                  12                                                    7                                                     0                                                    0
  Van Deun [@pone.0006914-VanDeun1]            58               40                                   8                                                    7                                                     0                                                    3
  Ward [@pone.0006914-Ward1]                   44               38                                   2                                                    3                                                     0                                                    1
  Yew [@pone.0006914-Yew1]                     72               51                                   6                                                    6                                                     0                                                    9
  Summary                                     191              62%                                  11%                                                  13%                                                    2%                                                   8%
  CI                                                        \[57--67\]       [@pone.0006914-Laserson1]--[@pone.0006914-Bartu1]   [@pone.0006914-Laserson1]--[@pone.0006914-Escudero1]   [@pone.0006914-World1]--[@pone.0006914-Mukherjee1]   [@pone.0006914-Sharma1]--[@pone.0006914-Avendano1]
  I^2^                                                         91%                                  80%                                                  94%                                                   93%                                                  94%
  P value                                                    \<0.0001                            \<0.0001                                              \<0.0001                                              \<0.0001                                             \<0.0001

10.1371/journal.pone.0006914.t003

###### Outcomes at Follow-up.
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  Author (Reference)                     Months FUP   Sample Size   Successful Outcome                       Death                        Relapse    Transfer of Care                        Failure                        Default
  ------------------------------------- ------------ ------------- -------------------- ------------------------------------------------ ---------- ------------------ --------------------------------------------------- ----------
  Avendano [@pone.0006914-Avendano1]         33           40                28                                 5                             4              0                                   1                              2
  Burgos [@pone.0006914-Burgos1]             24           48                31                                 11                            2              3                                   0                              1
  Escudero [@pone.0006914-Cox1]              24           25                21                                 0                             0              0                                   0                              4
  Goble [@pone.0006914-Ferrara1]             51           159               78                                 27                            0              0                                  32                              22
  Mitnick 08 [@pone.0006914-Mitnick2]        25           646              412                                134                            17             0                                  18                              65
  Shean [@pone.0006914-Park1]                24           491              239                                 68                            0              10                                 30                             144
  Van Deun [@pone.0006914-Uffredi1]          24           58                35                                 11                            2              0                                   3                              7
  Ward [@pone.0006914-VanDeun1]              15           44                38                                 2                             0              0                                   1                              3
  Yew [@pone.0006914-Ward1]                  25           72                46                                 8                             1              0                                   4                              13
  Summary                                    27           176              64%                                14%                            2%             1%                                 5%                             13%
  CI                                                                    \[56--72\]       [@pone.0006914-World3]--[@pone.0006914-Goble1]   \[0--4\]       \[0--2\]       [@pone.0006914-World2]--[@pone.0006914-Laserson1]   \[7--20
  I^2^                                                                     87%                                74%                           80%            70%                                 85%                            91%
  p value                                                                \<0.0001                            0.0002                       \<0.0001        0.0009                            \<0.0001                        \<0.0001

Covariate analysis {#s3a}
------------------

Predetermined covariates (gender, diabetes, alcohol abuse, HIV positive, BMI, smear positive, cavitary disease, surgical intervention, prior treatment, ≥6 drug resistance, fluoroquinolone use, and presence of XDRTB) were pooled and analyzed. The following covariates were associated with poor outcome: male gender (pooled OR for successful outcome 0.61, \[95% CI0.46--0.82\]), alcohol abuse 0.49 \[0.39--0.63\], low BMI 0.41 \[0.23--0.72\], smear positivity 0.53 \[0.31--0.91\], fluoroquinolone resistance 0.45 \[0.22--0.91\], and XDR resistance pattern 0.57 \[0.41--0.80\]. Surgical intervention 1.91 \[1.44--2.53\], no prior TB treatment 1.42 \[1.05--1.94\] and fluoroquinolone use 2.20 \[1.19--4.09\] were associated with successful outcome. Diabetes, cavitary disease, HIV and resistance to ≥6 drug were not statistically associated with worse outcomes. Two covariates, fluoroquinolone use and XDRTB, were analyzed for an association with death. The use of fluoroquinolones was associated with decreased mortality 0.30 \[0.15--0.61\], while there was a trend towards increased mortality with XDR ([Figure 2](#pone-0006914-g002){ref-type="fig"}).

![Summary of literature search and study selection.](pone.0006914.g002){#pone-0006914-g002}

Discussion {#s4}
==========

Drug resistant TB ultimately develops from the inadequate treatment of active pulmonary TB. There are multiple reasons for inadequate therapy; poor prescribing practices with insufficient treatment duration and poor drug selection are well-recognized contributors [@pone.0006914-Sharma1], [@pone.0006914-Raviglione1]. Systemic problems, through inadequate public health resources and unpredictable drug supplies also play a role [@pone.0006914-Mukherjee1]. In addition, irregular medication intake--whether from insufficient patient education, adverse events, or socioeconomic determinants--contribute to resistance. There are also a significant proportion of patients who acquire drug resistant disease because they live in an environment with a high prevalence of drug resistant disease.

Despite these well-known causes of drug resistance, our review of 36 observational studies revealed very high rates of default and transfer of care. The majority of unsuccessful outcomes at end of treatment were the result of these factors, with relapse accounting for only 2% of patients in follow-up. Moreover, default appears to be a global phenomenon, with rates over 15% in several countries, including Korea (32%) [@pone.0006914-Kim2], Taiwan (29%) [@pone.0006914-Chiang1], Russia (20%) [@pone.0006914-Keshavjee1], Italy (17%) [@pone.0006914-Ferrara1], Spain (16%) [@pone.0006914-Escudero1], South Africa (29%) [@pone.0006914-Shean1], Argentina (20%) [@pone.0006914-Palmero1], and Peru (19%) [@pone.0006914-Mitnick2]. With the advent of DOTS and DOTS-Plus strategies, MDRTB rates have improved in some high prevalence countries, such as Latvia where new MDR cases have decreased more than two-fold between 2000 and 2007 (V. Leimane, unpublished data). Yet under these improved circumstances, published default rates were above 10% [@pone.0006914-Leimane1].

The consequences of inadequate therapy are also apparent in our data. On pooled analysis we have shown that prior treatment, fluoroquinolone resistance, and XDRTB were all associated with poor outcomes. While resistance to fluoroquinolones was associated with worse outcomes, fluoroquinolone use was associated with successful outcomes. This finding is consistent with several observational studies showing that fluoroquinolones are highly effective in MDRTB treatment [@pone.0006914-Chiang1], [@pone.0006914-Tahaoglu1], [@pone.0006914-Torun1], [@pone.0006914-Yew1], [@pone.0006914-Yew2], [@pone.0006914-Chan2], [@pone.0006914-Hong1]. The WHO Green Light Committee recommends that MDR patients receive a fluoroquinolone when their culture results reveal a susceptible isolate [@pone.0006914-World3]. But judicious use of fluoroquinolones is crucial in suspected and confirmed cases of TB if we hope to impede the development of further resistance [@pone.0006914-Mitnick2]. What is less clear is the role of newer generation fluoroquinolones in the treatment of fluoroquinolone resistant MDRTB. The findings of Yew suggest that newer generation fluoroquinolones may be effective against ofloxacin resistant strains [@pone.0006914-Yew2]. Further studies will be necessary to clarify the role of fluoroquinolones in this population. The emerging XDRTB literature may be a resource to explore this issue.

Since the seminal report on XDRTB from KwaZulu-Natal, South Africa [@pone.0006914-Ghandi1], multiple studies have reported outcomes of XDRTB treatment [@pone.0006914-Banerjee1], [@pone.0006914-Keshavjee1]--[@pone.0006914-Kwon1], [@pone.0006914-Mitnick3], [@pone.0006914-Chan3]--[@pone.0006914-Migliori1]. In the XDR cohorts examined in our study, the majority of patients had poor outcomes, despite low HIV rates. The global burden of XDRTB reflects the multiple deficiencies of tuberculosis control [@pone.0006914-Raviglione1]. With aggressive, comprehensive individualized therapy, programs can improve XDRTB outcomes [@pone.0006914-Mitnick3]. But, targets for interventions need to be better defined.

An obvious target for comprehensive interventions is in the management of co-morbidities. The most commonly reported co-morbidities in our selected studies were alcohol abuse, low BMI, and diabetes. The association between poor outcome with BMI and alcohol abuse is not unexpected. Body mass index, as a symptom of severe disease and low socioeconomic status requires aggressive intervention [@pone.0006914-Mitnick2]. To our knowledge, there are no comparative studies examining the optimal nutritional intervention in an MDRTB population. Moreover, there are no evidence-based guidelines on nutritional supplementation in adults or children [@pone.0006914-Abba1]. Further studies on MDRTB could not only include a baseline nutritional intervention, but also study the impact of various nutritional interventions on MDRTB outcomes. Meanwhile, alcohol abuse has been associated with poor TB outcome in several studies [@pone.0006914-Cox1], [@pone.0006914-Keshavjee1], [@pone.0006914-Shean1], [@pone.0006914-Shin1], [@pone.0006914-Nathanson1] and measures to improve care for alcohol abuse should be undertaken. A recently published study in Tomsk, Russia, describes successful adoption of a program to address alcohol use disorders, with the intent to measure outcomes [@pone.0006914-Mathew1].

Diabetes mellitus is also a well-described co-morbidity in MDRTB patients. Not only are diabetics prone to reactivation TB [@pone.0006914-Jeon2], they may also be at increased risk of developing MDRTB [@pone.0006914-Kim3], [@pone.0006914-Bashar1]. The reasons for this are unclear, but based on our pooled data, diabetics do not appear to have worse outcomes with MDRTB. These results stand in contrast to previously published literature on drug sensitive TB [@pone.0006914-PablosMendez1], and may relate to our small sample size of 68 diabetics.

Lastly, our data supports the role of surgery in the management of MDRTB. Surgical patients appear to have superior outcomes---this may reflect the practice of performing surgery on less sick, adherent patients who have responded favourably to initial medical therapy. Although trials in surgery are inherently difficult, they should be undertaken to examine the role of surgery in MDRTB patients. Multiple surgical series have been published on this topic and could be examined for predictors of successful outcomes. In addition, future trials examining the role of surgery on highly resistant strains such as fluoroquinolone and XDR strains may be valuable.

Our study has several limitations. The most important is our inability to identify any randomized control trials (RCTs). Instead we relied exclusively on observational data for treatment outcomes. This likely introduced confounding to our pooled analysis, since crude outcomes, rather than adjusted odds ratios were reported for most trials. Moreover, the analysis of outcomes and pre-determined covariates used heterogeneous data from variable treatment regimens. The trends introduced by this analysis are subject to bias and should be interpreted with caution. Our quality analysis also likely introduced bias since only systems with resources for record keeping, second-line therapy and prolonged treatment and follow-up were included for analysis. These systems likely have improved outcomes compared with the many poorly resourced TB control programs throughout the world. Indeed, a recent editorial noted an "exceptionality" bias when commenting on reported XDRTB outcomes [@pone.0006914-Raviglione2].

Of note, our treatment outcome definitions were heterogeneous between populations. Of the 36 studies included for analysis, only 12 studies (representing nine patient populations) met the outcome definitions proposed in WHO guidelines [@pone.0006914-World3], [@pone.0006914-Cox1], [@pone.0006914-Holtz1]--[@pone.0006914-Leimane1], [@pone.0006914-Mitnick3], [@pone.0006914-Shean1], [@pone.0006914-Shin1], [@pone.0006914-Torun1], [@pone.0006914-Tupasi1]. The effect of this heterogeneity is difficult to assess. We observed, however, that several studies did not use the stringent culture-based outcome definitions such as *Cure* or *Failed*. This likely biased results towards more successful outcomes. Despite this, studies that used WHO outcomes showed similar outcomes: 62% \[5--69\] of patients had successful outcomes with a 15% [@pone.0006914-Laserson1]--[@pone.0006914-Holtz1] default and 10% [@pone.0006914-Mitnick1]--[@pone.0006914-Burgos1] death rate.

Another significant limitation is the lack of data on HIV positive patients. In total 143 of 6359 patients (2%) were known to be HIV positive, with the data from 39 patients available for outcome analysis. This limits the power to detect the effect of the presence of HIV infection. Some studies reported HIV infected populations with treatment and follow-up durations shorter than 12 and 18 months respectively [@pone.0006914-Ghandi1], [@pone.0006914-Frieden1], [@pone.0006914-Valway1]. Thus, our inclusion criteria for treatment duration and follow-up likely excluded a disproportionate population of HIV positive patients from our analysis. In addition, our criteria eliminated studies examining 'outbreaks' of MDRTB, where a more virulent strain spreads quickly through a community. Such outbreak investigations tend to have limited follow-up and outcome data given the urgency to report findings [@pone.0006914-Center1], [@pone.0006914-Center2].

Recently, a systematic review examining MDRTB treatment outcomes in 33 populations was published by *Orenstein et al*. [@pone.0006914-Orenstein1]. In this review, 62% of patients were classified as successful outcomes. Covariate analysis revealed that the proportion of patients with successful treatment outcomes did not significantly change for several individual covariates. The authors concluded that this likely reflected study heterogeneity. Similarly, our review examined MDRTB treatment outcomes. We have, however, focused on underlying patient and disease characteristics--such as diabetes, alcoholism, and smear positivity---while, *Orenstein et al*. focused on programmatic characteristics such as length of treatment and the use of Directly Observed Therapy. Overall, our outcomes do not differ markedly from those of *Orenstein et al.*, and we feel that our covariate analysis contributes to the literature on this topic.

Though treatment success remains dismally low in MDRTB populations, there is reason to be hopeful. With the advent of standardized nomenclature, outcomes of MDRTB treatment regimens can be evaluated with more precision. The addition of more comprehensive therapeutic strategies will also help improve outcomes. But, an evidence-based approach, in addition to comprehensive, individualized therapy, is necessary to contain MDRTB [@pone.0006914-Mitnick1]. Without high quality evidence to support therapeutic decisions, including data from high-risk populations such as HIV positive and diabetic patients, high mortality, default, and failure rates will persist.
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